|
|
Dr. Bauer specializes in the use of extremely large heterogeneous datasets, coined as Big Data. His work focuses specifically on furthering the understanding of cancer biology with the inclusion of multiple types of molecular data to get a more complete picture of cancer biology. Read more>
|
|
|
Cancer Institute Research Programs
|
|
Developmental Therapeutics
Leader: Hong-yu Li, Ph.D.
This is the fourth of a four-part series highlighting the Cancer Institute research programs and opportunities for inter- and intraprogrammatic collaborations. The Cancer Institute research programs provide a collaborative environment for the conceptualization and conduct of basic, translational and clinical cancer-focused research. Co-leader positions are available for some of the programs.
|
|
|
The Developmental Therapeutics program at the UAMS Winthrop P. Rockefeller Cancer Institute focuses on developing hypotheses and evidence-based translational strategies for improved cancer treatment.
Hong-yu Li, Ph.D., professor in the UAMS College of Pharmacy Department of Pharmaceutical Sciences, serves as program leader.
The Cancer Institute’s largest research program, Developmental Therapeutics was originally known as the Therapeutic Science program. It recently received a name change and more focused mission emphasizing technology associated with the discovery and development of small molecule drug agents and biological therapies. This discovery phase is followed by validation using preclinical and clinical models.
“Our focus is both highly translational and highly collaborative. If we want to achieve results, we must collaborate with others, not only in this program, but also across UAMS, nationally and internationally. Collaboration is a priority in our success,” Li said.
The program’s main goals emphasize the optimization of therapies that connect the bench to the bedside through the discovery and development of new drugs for new cancer targets. By establishing a Phase 1 Clinical Trial Unit at the Cancer Institute, scientists could directly connect patient outcomes to their preclinical studies.
“A Phase 1 Unit would allow us not only to take our discoveries from bench to bedside, but also from the bedside back to the bench. If we found new mutations or biological targets, we can go back to the bench and continue working on those to further develop and improve the new drugs,” Li said.
Ultimately, the program aims for its members and collaborators to translate their research into new drugs for the marketplace. This directly ties to the Cancer Institute’s quest for National Cancer Institute (NCI) Designation, as NCI requires evidence of patents received and companies formed based on research accomplished at the centers.
The fact that program members have a wide range of expertise and practical experience in developing Investigational New Drug (IND) applications and conducting IND studies and clinical trials, gives the program an advantage.
“NCI wants to see us translate our basic research into something useful for the public. That, of course, is our ultimate goal as well,” Li said.
|
|
|
Pew-Stewart Scholars for Cancer Research
|
|
The Winthrop P. Rockefeller Cancer Institute invites outstanding junior faculty engaged in cancer research to submit application materials for consideration as the Cancer Institute 2021 nominee for the Pew-Stewart Scholar. The Pew-Stewart Scholars for Cancer Research program supports promising assistant professors engaged in innovative research working toward a cure for cancer. The award provides $75,000 per year for four years, for a total award value of $300,000.
Click here for more information and eligibility requirements.
If you wish to be considered for nomination, please submit the following materials to Dorothy Graves at dagraves@uams.edu by midnight on Monday, May 11, 2020:
- Summary of your research project
- CV
- Letter of support from your division and/or department chair
An internal selection committee will review all applications and choose a nominee to represent the Cancer Institute in this highly competitive funding opportunity. You will be notified no later than May 18, 2020 as to the status of your application.
This information is also available on the Cancer Institute's website. Please contact Dorothy Graves with any questions.
|
|
|
Cancer-related Research Funding Opportunities
|
|
Extramural Opportunities
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
DoD Lung Cancer, Concept Award
Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional)
Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional)
DOD Prostate Cancer, Early Investigator Research Award
Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed)
DoD Neurofibromatosis, Investigator-Initiated Research Award
DoD Neurofibromatosis, Clinical Trial Award
DoD Neurofibromatosis, Exploration – Hypothesis Development Award
DoD Neurofibromatosis, New Investigator Award
DoD Neurofibromatosis, Early Investigator Research Award
DoD Neurofibromatosis, Synergistic Idea Award
DoD, Breast Cancer, Breakthrough Award Levels 1 and 2
DoD, Breast Cancer, Breakthrough Award Level 3
DoD, Breast Cancer, Breakthrough Award Level 4
DoD, Breast Cancer, Innovator Award
DoD Breast Cancer, Era of Hope Scholar Award
DoD Breast Cancer, Transformative Breast Cancer Consortium Award
DoD Melanoma Research Program, Idea Award
DoD Melanoma Research Program, Mid-Career Accelerator Award
DoD Melanoma Research Program, Team Science Award
DoD Melanoma Research Program, Technology Development Partnership Award
DoD Melanoma Research Program, Translational Research Award
DoD Melanoma Research Program, Translational Research Award – Collaborator Option
CTSA Supplemental Funding Opportunities
NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)
Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award, (U01 Clinical Trial Optional)
Foundation and Intramural Funding Opportunities
Pew-Stewart Scholars for Cancer Research
|
|
Know someone who needs to be added to our email list? Send their name to Susan Van Dusen, communications manager.
|
|
|
|
|
